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that of physicians’ preferences for middle-aged patients across
most beneﬁt levels. Compared to adult patients, parents have
greater risk tolerance for treating severe CD symptoms, and
smaller risk tolerance for treating moderate CD symptoms.CON-
CLUSION: Respondents indicated they are willing to accept
deﬁned mortality risks in exchange for clinical efﬁcacy and that
acceptance is affected by the degree of beneﬁt, the patient’s
characteristics and the nature of the SAE. Understanding risk-
beneﬁt preferences can assist in identifying appropriate treat-
ments and in informing welfare-enhancing regulatory decisions.
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BACK PAIN IN GERMANY:ARETHERE DIFFERENCES
CONCERNING HEALTH-RELATED QUALITY OF LIFE (HRQOL)
IN PATIENTSTREATED ACCORDINGTO GUIDELINES,
GUIDELINE INDEPENDENT AND PATIENT SELF-TREATMENT?
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1Kendle GmbH, Munich, Germany, 2Pﬁzer Pharma GmbH, Karlsruhe,
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OBJECTIVES: Back pain has a considerable impact on HRQoL,
even with new medications, treatments and guidelines the degree
of suffering for patients is high. The objective was to compare
HRQoL for patients with back pain in Germany for three
different treatment groups (guideline-, non-guideline- and self-
treatment-group). METHODS: Patients were consecutively
recruited by physicians in general practice (n = 54) in 2005.
Patients were categorized into the three groups according to
pre-speciﬁed algorithms. All groups completed the generic SF-36,
and the disease speciﬁc FFbH, von Korff Index and PHQ-D
questionnaires. In addition, a retrospective chart review was
conducted. HRQoL data was compared between the groups.
RESULTS: A total of 145 patients took part in this study
(n = 29 guideline-group, 44 non-guideline-group, 72 with self-
treatment). Patients in the self-treatment-group were younger
than patients in guideline- or non-guideline-group (49.8 vs. 59.4
vs 57. 4 years, p = 0.0021). The groups did not differ signiﬁcantly
in gender or other socio-demographic characteristics. The von
Korff Index was lowest (i.e. poorer) in the self-treatment-group
and highest in the guideline-group (p = 0.0077). Regarding
SF-36, patients in the guideline-group had the lowest physical
(30.2  8.5) and mental (41.2  13.5) component scores, only
the differences regarding physical component were statistically
signiﬁcant between the groups (p < 0.0001), those regarding
mental component were not (p = 0.2875). Regarding PHQ-D
items, the groups did not differ in frequency of major depressive
and other depressive symptoms. The guideline-group had signiﬁ-
cantly higher burden of somatoform symptoms compared to the
other two groups (p = 0.0219). The self-treatment-group had the
highest FFbH-R total score (67.7  21.5) compared to other two
groups (p = 0.0056). CONCLUSION: From the here collected
data, it seems that patients who are treated according to guide-
lines have reached a higher degree of suffering (poorer HRQoL)
compared to those patients with either treated without guidelines
and/or treat themselves. Further research is warranted to conﬁrm
our ﬁndings.
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USINGTHE FACT-NEUROTOXICITYTO EVALUATE QUALITY
OF LIFE IN CANCER PATIENTS FROM ACROSSTHE GLOBE
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OBJECTIVES: Translation of PRO measures is an essential com-
ponent of research methodology in preparation for multinational
clinical trials. The FACT-Neurotoxicity (FACT-Ntx) is used to
evaluate the quality of life of cancer patients suffering from
neurotoxicity, a side effect of certain treatments. This study set
out to linguistically validate the FACT-Ntx for use in Denmark,
India, Lithuania and South Africa. METHODS: The study
sample consisted of 176 patients (96 males and 80 females), with
varying cancer diagnoses and a mean age of 51 years, speaking
11 languages: Afrikaans (15), Danish (25), Gujarati (15), Hindi
(15), Kannada (15), Lithuanian (15), Malayalam (15), Marathi
(15), Punjabi (15), Tamil (15) and Telugu (16). The FACT-Ntx
was translated according to standard FACIT methodology.
Patients diagnosed with any stage cancer on any treatment and
experiencing neurotoxicity completed the respective translated
version and then participated in cognitive debrieﬁng interviews.
Statistical analyses (descriptive statistics, one-way ANOVA and
reliability analyses) were performed on the quantitative data.
Participant comments were analyzed qualitatively. RESULTS:
The FACT-Ntx translations showed good reliability and linguis-
tic validity. The internal consistency of all languages combined
was 0.86, and all items correlated at an acceptable level. In
general, the Ntx score differed across self-reported Performance
Status Rating (PSR) groups (nonparametric Kruskal-Wallis test
p < 0.0001). A nonparametric Generalized Linear Model (GLM)
approach (with multiple comparison adjusted signiﬁcance level
0.017) showed a difference between ‘PSR = 0’ and ‘PSR = 1’
(p = 0.0002) and a difference between ‘PSR = 0’ and ‘PSR = 2’
(p < 0.0001), both with ‘PSR = 0’ patients reporting less neuro-
toxicity. CONCLUSION: The FACT-Ntx has shown acceptable
reliability and linguistic validity in 11 languages. The instrument
has also shown adequate sensitivity in differentiating patients
with no symptoms and normal activity from patients reporting
some symptoms. We consider these translations acceptable for
use in international research and clinical trials.
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OBJECTIVES: To facilitate the comparison of net beneﬁts of
cancer treatments in clinical trials by developing and validating
a system to convert data from a QoL instrument into precise
and optimally weighted global QoL measures and utilities.
METHODS: Two-hundred cancer patients completed the Utility-
Based Questionnaire-Cancer (UBQ-C), a validated 34-item
cancer-speciﬁc instrument which includes scales of health status,
overall QoL, disabilities and distresses. Patients were interviewed
to elicit time trade-off (TTO) utilities for their own health states.
A global QoL measure was derived from a weighted combination
of the UBQ-C scales based on linear regression of health status
on the individual scales. An equation to convert global QoL into
utility was derived. Validity was examined using baseline data
from a RCT of advanced breast cancer chemotherapy (n = 290).
RESULTS: The weighted global QoL measure was more precise
than the single-item QoL scales. Median scores (IQR) were much
lower for the weighted global QoL measure: 0.77 (0.65, 0.85)
than for the direct TTO utility: 0.98 (0.85, 1.0). The best model
to predict utility from weighted global QoL was a power
transformation: TTO = 1-(1-global QoL)2.1. The measures dis-
criminated between RCT subjects with good and poor per-
formance status: mean (95% CI) derived utility scores for
ECOG 0-1 = 0.91 (0.89, 0.92), ECOG 2-3 = 0.75 (0.68, 0.81),
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p < 0.0001. Subjects with lower scores had worse survival: HR
1.6 (95% CI 1.2, 2.0), p < 0.0002. CONCLUSION: QoL mea-
sures underestimate utilities. The weighted global QoL and
utility scores had discriminative and predictive validity in
advanced cancer. Our work enables QoL data obtained with a
simple questionnaire to be converted into optimally weighted
measures that can be used in clinical trials to: describe the net
effect of cancer treatments on QoL; evaluate trade-offs between
quality and quantity of life using quality-adjusted survival analy-
sis; and do cost-effectiveness analyses based on cancer patients’
preferences.
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OBJECTIVES: To analyze the effectiveness of Darbepoetin alpha
and Epoetin alpha administered in patients with chemotherapy-
induced anaemia (CIA) in the German setting considering the
dosing schedules recommended in Germany. METHODS: Pub-
lished prospective, randomized and controlled studies with either
Epoetin alpha administered once weekly (EPO-QW), Darbepo-
etin administered QW (DARB-QW) and once every three weeks
(DARB-Q3W) were extracted. Mean haemoglobin area-under-
the-change-curve (HB-AUC) was selected as the effectiveness
parameter, calculated by inclusion of all available haemoglobin
values in the chosen time frame of 12 weeks. Mean administered
doses and transfusion requirements were analysed. Number of
study patients were accounted for. RESULTS: Eleven study arms
were identiﬁed satisfying the inclusion criteria. Mean baseline
HB for EPO-QW, DARB-QW and DARB-Q3W varied between
9.5–10.4 g/dl, 9.4–9.9 g/dl, and 9.8–9.9 g/dl respectively. The
increase in HB levels from baseline to week 12 varied between
about 1.0 g/dl–2.9 g/dl, 1.1 g/dl–1.6 g/dl, and about 1.0 g/dl.
Calculated mean HB-AUC value for EPO-QW, DARB-QW
and DARB-Q3W were 11.75, 8.84 and 8.08, respectively.
Mean administered doses reported were 39,949 IU / week and
42,714 IU / week for EPO-QW, 2.2 mg/kg weekly, 1.59 mg/kg
weekly, 2.05 mg/kg weekly for DARB-QW and 1.87 mg/kg weekly
mean dose per kg for DARB-Q3W. Information on transfusion
rates differed, for two study-arms transfusion requirements were
not reported at all. CONCLUSION: Comparative studies are not
available for the recommended and labeled regimens in Germany.
Quality and amount of reported data needed for comparing
clinical effectiveness from different study arms differ very much.
Administered doses, transfusion rates and detailed HB increase
were not available for all studies. Considering HB-AUC as
the key comparison criterium Epoetin alpha administered once
weekly is more effective.
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OBJECTIVES: Despite demonstrated efﬁcacy of anthrayclines in
metastatic breast cancer (MBC), strong evidence links these
agents to development of reduced left ventricular ejection frac-
tion (LVEF) and congestive heart failure (CHF). We examined the
cost-effectiveness of using pegylated lipisomal doxorubicin (PLD)
to reduce cardiotoxicity. METHODS: A Markov model was
developed to simulate the use of PLD vs. conventional doxoru-
bicin (DOX) in the ﬁrst 48 weeks after initiation of therapy. Our
reference case was a 58 year old female newly diagnosed with
MBC. Data from a large-scale clinical trial was used to model the
incidence of CHF. The perspective was the provincial authority in
Ontario, Canada. Costs included direct costs of chemotherapy,
oncology and hospital services for managing MBC, as well as
medical management for treating cardiotoxicity. Since trial data
showed that patients with prior anthracycline exposure (15%)
had a relative risk of 2.8 for LVEF, and 4.1 for progression to
CHF, we adjusted for prior anthracycline exposure which is
greater in the adjuvant setting (80% in Ontario). A previously
developed cardiotoxicity risk model was used to identify high-
risk patients. Analyses were performed for: 1) all patients, 2)
subset of high-risk patients. RESULTS: For DOX, 40% experi-
enced cardiotoxicity, with 18% developing CHF. These rates
were 54% and 33% in high-risk patients. For PLD, no patients
developed CHF, but 9% overall and 14% of high-risk patients
developed LVEF. Using PLD instead of DOX was associated with
an incremental cost of CAD$75,513 per patient spared CHF,
$49,952 in high-risk patients. CONCLUSION: In the ﬁrst treat-
ment year, the greatest cost-effectiveness gain was avoidance of
CHF in high-risk patients. In Ontario, where the vast majority of
patients are high-risk, a large percentage of patients would be
expected to avoid CHF by using pegylated lipisomal doxorubicin
instead of conventional doxorubicin.
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OBJECTIVES: To measure the mean incremental differences in
health services utilization and costs for individuals infected with
HIV compared with individuals not infected with HIV who
reside in the Downtown Eastside (DTES) of Vancouver, Canada.
METHODS: We utilized data from the Community Health And
Safety Evaluation (CHASE) Project, a prospective cohort study
undertaken to measure health care utilization. A representative
sample of residents living in the DTES were recruited beginning
February 2003 and followed until March 31, 2004. Self-reported
information was collected at baseline and included sections on
sociodemographics, education, employment, housing, and illicit
drug use. This information was linked to administrative health
records on HIV-status, hospitalizations, outpatient consultations,
and dispensed medications. Health expenditures included costs
of hospitalizations (estimated using length of stay and the mean
per-diem), outpatient visits and medications and were analyzed
using random effects linear regression models and reported in
2004 $CDN. RESULTS: The analysis consisted of 2,905 indi-
viduals who were successfully linked with at least one of the
linked databases. There were 459 (15.8%) HIV-positive and
2456 HIV-negative participants. All utilization and cost estimates
were signiﬁcantly higher for individuals infected with HIV, both
crudely and after adjustment. Individuals infected with HIV had
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